ArticleSchizophrenia (Heidelberg, Germany)2025
A frame network study of first-episode schizophrenia, ultra-high risk, and healthy populations.
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a complex neuropsychiatric disorder, and the abnormalities in brain networks during its early stages remain incompletely understood. Previously, we identified a stable high-intensity functional network, termed the "Frame Network," in healthy individuals and observed its aberrations in schizophrenia patients. This study aimed to utilize this network to explore disconnection abnormalities in early-stage schizophrenia. This study compared drug-naïve first-episode schizophrenia patients (FES, n = 83), ultra-high risk of schizophrenia (UHR, n = 65), and matched healthy controls (HC, n = 67). Frame networks were analyzed across groups, and differences were assessed using networks from healthy people (HP) derived from stable connections in two public datasets. Network-Based Statistics (NBS)-predict identified connections for a disease classification model. FES patients were divided into two subtypes, and connections related to negative symptoms were identified using Connectome-based Predictive Modeling (CPM). UHR and FES patients showed increasing abnormalities in frame connections compared to controls. HP and FES frame networks effectively differentiated groups. Connections crucial for classification were found in the prefrontal motor cortex. Patients divided into two subtypes showed distinct pathological presentations. Frame networks predicted negative symptoms effectively. Variations in regions such as the visual and prefrontal cortex were observed based on symptom severity, indicating diverse underlying connection differences in the clinical heterogeneity of schizophrenia. Our findings indicate that Frame Network abnormalities likely play a significant role in early-stage pathological processes of schizophrenia and show promise as biomarkers for disease classification and symptom prognosis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.